Arestat™ comprises two fundamentally different aspects of
our platform stabilization technology. Both utilize excipients
and buffers approved by the FDA and EMEA in an unconventional
manner to achieve the desired stability.
Both platform technologies are available for licensing for applications involving
therapeutic proteins, vaccines, medical devices and diagnostics.
Arecor has adopted a flexible approach to accommodate the
requirements of their partners developing biopharmaceuticals,
medical devices or diagnostics. Once a feasibility study is
concluded or near completion, Arecor's partners are encouraged
to consider the next stage in product development. Through a
series of discussions Arecor is able to tailor a customised
approach for each partner under a research or collaborative
agreement. A research agreement allows partners access to
proprietary information for them to continue development within
their own facilities and to draw upon Arecor’s advice and support
when necessary. A collaborative agreement provides Arecor’s partners
access to ongoing assistance with the management of product development.
A Research or Collaborative agreement allows a partner to
continue the development of their product but it does not
permit them to commercialise the product or publish / patent
the results without the prior approval of Arecor.